



# University of Pittsburgh

*School of Medicine*

*Department of Critical Care Medicine*

600 Scaife Hall  
3550 Terrace Street  
Pittsburgh, PA 15261  
Fax: 412.647.8060

## CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY

**STUDY TITLE:** Strategies to Promote Resiliency (SPRY)-An Adaptive Randomized Clinical Trial of Metformin in High Risk Surgical Patients

**PRINCIPAL INVESTIGATOR:**

Dr. Matthew Neal  
University of Pittsburgh  
Departments of Surgery, Critical Care Medicine, and the Clinical and Translational Science Institute  
F1271.2 PUH  
200 Lothrop Street  
Pittsburgh, PA 15213  
Phone: 412.647.1158

Tamera Means, MD, MHS  
Clinical Research Coordinator  
412.383.1573

**SOURCE OF SUPPORT:** UPMC Internal Funds

**KEY INFORMATION:**

You are being invited to consider joining a research study. Participation in a research study is always voluntary. The first part of this form is a summary of the study. Please also read the Detailed Information section that follows before making a decision about participation in this study.

**Why are researchers doing this study?**

Increasing age is a risk factor for having complications after surgery. There are some

Page 1 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

studies suggesting metformin, a medication often used for diabetes, may be able to reduce inflammation as well as have other effects which may help with complications.

In this study, we want to look at whether or not metformin is able to improve your outcome and reduce complications after elective surgery.

### **What is involved in this study?**

You will be randomly assigned to receive one of 3 doses of metformin (500 mg, 1000 mg, or 1500 mg) or one of three doses of placebo (sugar pills). You will take this study drug starting tomorrow and continue to take this study drug for 90 days after your surgery.

If you participate in this study, you may have blood samples taken at up to 5 timepoints while you take the study drug. This blood would be stored without identifiers.

You may also complete questionnaires during this study.

### **What are some reasons I might choose to volunteer?**

Researchers are conducting this study because they do not know if metformin might be helpful. Their goal is to determine what might help future patients.

### **What risks are involved in the study?**

For those people who are assigned to take metformin, some people may experience mild stomach and digestive system side effects as outlined in the 'Potential Risks and Discomforts' section which follows. These are usually temporary and resolve with continued use of metformin.

Other minor risks are noted in the 'Potential Risks and Discomforts' section.

### **What other things should I consider?**

You will not be charged for costs associated with the study drug or for any procedures required by the study. Costs associated with your routine medical care, including your elective surgery and hospital stay, will still be your responsibility or that of your insurance provider.

### **Will being in this study help me?**

For those assigned to the placebo group, no direct benefit is expected. For those who will be taking metformin, it is not known if there will be any direct benefit to you.

### **What are my choices if I decide not to be in this study?**

If you decide not to join the study, this will have no effect on your elective surgery.



## **DETAILED INFORMATION**

### **INTRODUCTION:**

This study is being conducted to determine if people taking metformin have better outcomes and fewer complications after having elective surgery compared to people not taking metformin. Metformin is a medication commonly given by doctors to reduce blood sugar in people with diabetes (a disease where you have higher than normal blood sugar). The use of metformin in this research study is investigational.

“Investigational” means that the use of metformin for the purpose of improving outcome after surgery is not approved by the United States Food and Drug Administration.

In this consent form, “you” and “your” always refers to the subject and “we” always refers to the study team.

You are being asked to participate in this research study as you are scheduled for an elective surgical procedure in a UPMC facility as part of your routine care. You may be eligible for participation in this research study if you are at least 60 years of age and do not have diabetes. You may also be eligible if you are younger than 60 years of age and have certain chronic medical conditions. Women enrolled into this study must be post-menopausal, which means that you have not had a menstrual period within the last 12 months.

### **DESCRIPTION OF THE RESEARCH**

A total of up to 2,000 men and women may be enrolled into this research study over the next two years at the University of Pittsburgh/UPMC.

Your study participation will begin on the day you are seen in the clinic for the pre-operative evaluation prior to your surgery. As part of this study, you will take a study drug prior to your operation and then for ninety (90) days after the date of your surgery. Medical record information may be collected for approximately a year after your completion of the study drug.

### **WHEN THE INVESTIGATOR IS ALSO THE CARE-PROVIDER:**

For some of you, your physician is involved as an investigator in this research study. Before agreeing to participate, or at any time during your study participation, you may discuss your care with another doctor who is not associated with this research study. You are not under any obligation to participate in any research study offered by your physician.



## STUDY PROCEDURES:

If you decide to take part in this research study, certain research procedures may occur.

### Clinic Visit Before Your Surgery:

- You may answer questions regarding your demographic details (date of birth, race, etc.)
- You may answer a few general questions about your medical history, allergies, and your use of alcohol to verify that you are eligible to participate in this study.
- You may be asked to provide contact information (name, phone number, mailing address, e-mail address) for you, your spouse/partner, and maybe for another friend/relative. This contact information is collected as the study team may need to contact you throughout the study. If the study team cannot reach you, they would then try to reach one of the other individuals you have identified for the study team.
- You may have a blood sample drawn. Blood will be drawn to store some blood for future testing to be able to compare how aspects of your blood change as you progress through the study. The blood would likely be drawn by putting a needle into a vein in your arm. About four (4) tablespoons of blood may be taken for this study at the same time as blood is drawn for testing required for your surgery if needed. Your blood would be drawn by a nurse or another skilled medical professional. The blood draw should take about ten minutes. Other blood samples may be taken at other times during the study. When possible, these blood samples would be drawn at the same time as standard of care blood is drawn.
- You will be randomly assigned by chance to receive one of the following study drugs to take one time daily by mouth:
  - 500 mg (1 pill) metformin extended release (ER)
  - 1000 mg (2 pills) metformin extended release (ER)
  - 1500 mg (3 pills) metformin extended release (ER)
  - Placebo (1 pill)
  - Placebo (2 pills)
  - Placebo (3 pills)

A placebo is a sugar pill that looks like a metformin pill but does not contain any active drug. At the beginning of the study, an individual has a 37% (37 in 100) chance of receiving placebo and a 63% (63 in 100) chance of receiving one of the three metformin doses. Once an individual is assigned to receive placebo or metformin, the individual takes this study drug for the duration of the study.

As this study is designed to enroll people over 2 years, the likelihood that those who participate at a later time will receive metformin or placebo will change based on the number of individuals who have participated in the study up to that point.



If you are assigned to either the 1500 mg metformin extended release dose or the 3 pill placebo option, you will take 2 pills for the first 7 days. Starting on day eight, you will then take 3 pills. The reason to begin with the lower dose is that this will help to reduce possible side effects if you are taking metformin.

Both you and the study team will not know if you are taking metformin or placebo during the study. In the event of an emergency, it is possible for the study team to learn what study drug you are taking.

You should start to take the study drug the morning after your pre-operative clinic visit. You should take the study drug every day. You should take the study drug with food to minimize GI effects. You should bring your current study drug pill bottle with you on the date of your surgery. Depending upon when your surgery is scheduled, the UPMC Investigational Drug Service may need to send you additional study drug by mail. It is important that you take all of the study drug in the current study drug pill bottle before starting to take study drug from a new study drug pill bottle received in the mail.

You should continue to take the study drug through the day of your elective surgical procedure and for 90 days following the date of your surgery. The study drug will only be available to you during the study.

- You will be given a wallet card that indicates that you are participating in this study. This card lists that you may be taking metformin. You should carry this wallet card with you and show this wallet card to any health care professional you see while you are taking the study drug.
- We may contact your PCP and other members of your health care team to let them know of your involvement in this study. These communications could occur at various times throughout your study participation.
- As part of the process for you to decide to participate in this study, you will speak with one of the investigators involved with this study. If the investigator cannot promptly come to your clinic location, this interaction may occur via phone or via remote video conference. The purpose of your conversation with the investigator is for the investigator to ensure that you understand what is involved in study participation and to ensure all of your questions have been answered. Following the conversation with the investigator, either in person or by telephone/video conference, this informed consent will be signed by you and by the investigator. A copy of the informed consent will be given to you.

These research procedures will likely take place in the clinic where you are having your office visit before surgery. The research procedures may add approximately 45 minutes to your visit.

Prior to the day of surgery, ideally within 48 hours of study enrollment:

- You may receive a phone call from a member of the Long Term Outcomes Core team. The purpose of this phone call is to remind you of the importance of



bringing your study drug pill bottle with you when you come to the hospital for your elective surgery.

- During this phone call, a member of the Long Term Outcomes Core may ask you some questions about your general health and to assess your thinking and memory. This phone call should take about 15 minutes.

#### Day of surgery:

- You should give your study drug pill bottle to hospital staff personnel when you arrive at the hospital for your surgery. Your study drug pill bottle will be kept by hospital personnel while you are in the hospital. You will continue to take the study drug while you are in the hospital.
- You may have a blood sample drawn from the intravenous (IV) line that is inserted in your arm for your surgery or directly from a vein. About four (4) tablespoons of blood may be taken. Your blood would be drawn by a nurse or another skilled medical professional. The blood draw should take less than ten minutes.
- We may review your medical records and collect information related to your surgery and the medications you receive for your surgery as well as your general health. We may continue to review and collect this kind of information while you are in the hospital.

These research activities should take about 25 minutes.

#### After surgery:

- You may have blood drawn from the intravenous (IV) line that was inserted in your arm for your surgery or directly from a vein. About three and a half (3.5) tablespoons of blood may be taken at this time. Your blood would be drawn by a nurse or another skilled medical professional. The blood draw should take less than ten minutes and should occur in your hospital room.

#### During your hospital stay:

- You will continue to receive the study drug during your hospital stay. We may decide to suspend giving you the study drug if you have certain types of difficulties as a result of your surgery.

#### Day 3 after surgery or immediately prior to hospital discharge if earlier than Day 3:

- You may have blood drawn from the intravenous (IV) line inserted in your arm for your medical care or directly from a vein. About three and a half (3.5) tablespoons of blood may be taken at this time. Your blood would be drawn by a nurse or another skilled medical professional. The blood draw should take less than ten minutes.



#### Day of hospital discharge:

- You should be given another pill bottle containing the same study drug as before your surgery. You should continue to take the study drug for a total of 90 days since the date of your surgery.

These research procedures should take about 15 minutes and would take place in your room at the hospital before you leave the hospital to go home.

#### Follow-up visit approximately 2-3 weeks after surgery (Usual Care):

- You may have blood drawn from a vein in your arm. About three and a half (3.5) tablespoons of blood may be taken for this study. Your blood would be drawn by a skilled medical professional. The blood draw should take about ten minutes and would take place in the clinic where you see your doctor or in a nearby UPMC location.

#### Phone call 30 days (+/- 7 days) after surgery:

All subjects participating in this study may receive a phone call from the Long Term Outcomes Core who may ask you questions about your general health, your taking of the study drug, your general level of physical activity, and about whether you have seen any doctors/been to the hospital since your surgery. This phone call should take about 10-15 minutes.

#### Phone call 90 days (+ 28 days) after surgery:

**If you are not participating in the Motor Assessment Group (see below),** the Long-Term Outcomes Core may contact you via telephone to ask you the same kinds of questions as asked during the 30-day call. You may also be asked some questions to assess your memory, attention, and thinking skills.

This phone call should take about 30-35 minutes.

For those subjects who completed their 90 day questionnaires via phone call with the Long Term Outcomes Core, you will be reminded to discard the wallet card.

### **MOTOR ASSESSMENT GROUP**

**For those subjects who live within 20 miles of Oakland and are over the age of 65,** you may be asked to come in to the offices of the Department of Critical Care Medicine in Oakland to be a part of a Motor Assessment Group. Being a part of the Motor Assessment Group would be an in-person visit at 90 days (+28 days after surgery) rather than a phone call.

The goal of the Motor Assessment Group is to determine if people taking metformin have differences in their muscle strength after surgery compared to people not taking

Page 7 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

metformin. The Motor Assessment Group could enroll approximately 670 subjects.

During this visit, members of the Long Term Outcomes Core may ask you similar questions to those asked during the phone call 30 days after surgery. You may also be asked some questions to assess your memory, attention, and thinking skills.

In addition, you may have your grip strength measured and be asked to walk as far a distance as you can walk on a 50-foot (out and back) course in 2 minutes.

These interactions should take approximately 90 minutes.

During this visit, you will be reminded to discard the wallet card.

If the study team should determine that these questionnaires would be best collected via a phone call rather than via an in-person visit, a phone call would be scheduled with you to complete these questionnaires.

### **MICROBIOME SUB-STUDY**

We are interested to determine if there are differences in the microbiome (the microorganisms such as bacteria and their genetic material that are present in or on the human body) for people who are taking metformin as compared to people who are taking placebo. In order to determine these differences, up to 1000 subjects may be asked to provide stool specimens as part of a Microbiome Sub-study.

Clinic visit before your surgery:

- You may be asked to provide a stool specimen prior to your surgery. You would be instructed on how to collect a stool specimen at home. We would give you instructions and a container, which is placed on your toilet, so you can collect the stool. You will place a small amount of stool in a special tube. You would be given a pre-paid envelope to mail the sample back to the study team for processing and storage. If you are asked to provide a stool specimen prior to your surgery, you will be asked to provide other stool samples at other times during the study.

Day of surgery:

- You may have a rectal swab collected. Once you have been taken to the operating room and given medications for your surgery to make you sleepy, a cotton swab would be gently inserted approximately 1 inch into your anus. The cotton swab would be gently swirled for 15-30 seconds and then removed. The swab may be sent to the study team for processing and storage. The purpose of collecting the rectal swab is the same as collecting stool specimens.

During your hospital stay:

Page 8 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038



- You may be asked to provide a stool specimen during your hospital stay. The stool specimen would be collected in the same way as the previous time. If you need help to collect the stool specimen, a nurse, another medical professional or study team member may assist with the collection. The stool would be placed in a special tube and sent to the study team for processing and storage in the same way as the previous specimen.

If you may not have a bowel movement in the hospital, you may be asked to provide a stool specimen from your first bowel movement following discharge from the hospital. If you had a bowel movement in the hospital, but stool specimen collection did not occur, you may be asked to provide a stool specimen from your next bowel movement following discharge from the hospital. You are asked to collect the stool specimen within 5 days of your surgery. You would be provided with a pre-paid envelope to mail the sample back to the study team.

Day of hospital discharge:

- We will provide you with the materials needed for the collection of another stool specimen before you leave the hospital as well as a pre-paid mailing envelope to return the stool sample to us.

Post-op clinic visit:

- We would like you to collect a stool specimen as close as possible to the time of the follow-up visit with your doctor (approximately 2-3 weeks after your surgery). You would follow the same procedure as before to collect the stool specimen.

### **MUSCLE BIOPSY SUB-STUDY**

Up to 200 of the subjects who take part in the Motor Assessment Group who are willing will be recruited to participate in the Muscle Biopsy Sub-study. We are interested to determine the effect metformin may have on muscle structure and on muscle cell functioning. In order to do so, we will collect samples of muscle tissue from up to 200 subjects who are participating in the Motor Assessment Group at two time points of the sub-study. We will compare the results with the results from strength testing completed as part of the Motor Assessment Group (Visit at 90 days (+ 28 days) after your surgery).

A sample of muscle may be obtained at up to 2 timepoints during this sub-study:

- While you are under anesthesia on the day of your elective surgery
- While you are awake during the Visit at 90 days (+ 28 days) after surgery. This muscle biopsy will occur in Radiology Procedure Unit B (RPU B) or on the 8<sup>th</sup> Floor of UPMC Montefiore Hospital, Translational Research Center

You will be given instructions on withholding certain medications which thin the blood or slow clotting time if you are prescribed them and agree to undergo the biopsy.



The muscle sample collection procedure involves using a needle to take a small piece of muscle tissue from the outside of your upper leg, about 4-6 inches above the knee. The skin will be cleaned and injected with local anesthetic (numbing medicine) to minimize any pain. A small incision about the size of this dash “\_” (1/4th of an inch) will be made in the skin, through which a needle about the size of the letter “O” is slowly inserted into the muscle. A piece of the muscle (about the size of a pea) is then removed with the needle, the skin is closed with a steri-strip and a light dressing is applied then a pressure wrap is placed over the dressing.

Muscle biopsies would be performed by physicians on the study team experienced in muscle biopsies.

Your clinical care team will address biopsy care needs while you are in the hospital and you will be given post-biopsy care instructions for the 90-day biopsy.

### **CONTINUED ACCESS TO MEDICAL RECORD INFORMATION**

We also would like to have permission to collect medical record information for over one year from the time you stop taking the study drug. We would collect information related to your general health such as test results, treatments, and doctor’s notes as well as information about any hospital admissions and emergency department visits. In order to collect this medical record information from non-UPMC facilities, you may be asked to sign a separate authorization which would permit the sharing of your non-UPMC protected health information with the study team.

### **DATA RETENTION/BLOOD, STOOL, AND MUSCLE BIOPSY SAMPLES**

All of the blood samples, stool samples, and muscle biopsy collected during this study will be placed in a specimen bank. The purpose of the specimen bank is to collect and store these samples for future research studies related to aging as well as to study various types of diseases and conditions. Your blood samples, stool samples, and muscle biopsy samples, as applicable, will be kept forever. Your past, current and future medical record information stored at UPMC will be available to be matched with your biological samples. This data will be stored in a controlled-access database. Your data, which may include your health information, your biological samples, and genetic data generated from your samples will be stored with a unique ID number, but will not be stored with your name. Your blood samples, stool samples, and muscle biopsy samples, as applicable, may be used by other investigators here at the University of Pittsburgh and UPMC and may be shared with other researchers, industry, or with a federal repository without additional consent from you. One collaborator who may receive a portion of your muscle biopsy samples is the University of Utah. Your muscle biopsy samples will not be stored long term at the University of Utah. When your biological samples are shared, they will be shared without identifiers. Data and samples may be shared for any research question.

It is also possible a portion of your muscle biopsy sample may be analyzed immediately



by investigators at the University of Pittsburgh.

Research data will be maintained for at least 7 years following closure of this research study.

Analysis of these samples may include genetic analysis as previously described.

Any genetic information obtained from these studies will not be entered into your medical records. No clinically relevant results will be returned to you.

As the research questions to be asked are unknown and as the meaning and significance of the results of any future unspecified testing of the biospecimens collected under this research study is unknown, personal results will not be disclosed to research subjects.

Your blood samples, stool samples and research data collected in this study may contribute to a new discovery or treatment. In some instances, these discoveries or treatments may be of commercial value and may be sold, patented, or licensed by the investigators and the University of Pittsburgh for use in other research or the development of new products. You will not retain any property rights, nor will you share in any money that the investigators, the University of Pittsburgh, or their agents may realize.

## POTENTIAL RISKS AND DISCOMFORTS

**Metformin:** The known risks are effects on your stomach and digestive system such as gas, loss of appetite, nausea, vomiting, diarrhea, and decreased levels of B12 (cobalamin).

These side effects are usually temporary and resolve with continued use of metformin.

There is a rare risk of something called lactic acidosis. This is the build-up of something called lactate in your blood. Lactate in your blood normally is harmful if there too much. Early signs of this are changes in your breathing and belly pain. Always call the study team if you have any concern.

You should not participate in this study if you know you have an allergy to metformin.

As with all medications, in very rare cases, the use of metformin may result in an allergic reaction. Some symptoms of allergic reactions include: rash, difficulty breathing, wheezing, sudden drop in blood pressure, swelling around the mouth, throat or eyes, a fast pulse, sweating. Please seek emergency treatment immediately if you experience these kinds of symptoms and then alert the study doctor and study staff if you have these symptoms as a very serious allergic reaction may be life-threatening.

The study drug could interact with other drugs such as carbonic anhydrase inhibitors,



gliptins, and cimetidine.

**Blood sampling:** You may experience temporary discomfort, bruising, pain at the blood draw site, and fainting (rare risk).

**Surveys/questionnaires:** Individuals completing questionnaires/surveys may experience mild frustration or boredom in completing these assessments.

Motor Assessment Group:

**Two-minute walk test:** You may become tired during this test, depending upon your general health. If you become tired, you may stop walking at any time.

**Grip strength test:** There are no known risks.

For Microbiome Sub-Study:

**Stool sample:** There are no known risks to providing a stool sample.

**Rectal swab:** The collection of the rectal swab may cause temporary mild discomfort following the procedure.

For Muscle Sub-Study:

**Muscle sample collection:** You may have pain, bleeding, bruising at the site of the incision. In rare cases, infection at the site of the muscle sample collection is possible. Some people may also faint at the sight of needles or blood. To minimize this risk, we would perform this procedure while you lie down. Careful sterile technique and local anesthesia should reduce the likelihood of any of these complications. The risk of pain during the muscle collection procedure is very small, because we will give you anesthesia (numbing medicine). In case, you feel anything more than pressure, you will tell us, and we would give you more numbing medicine until the area is completely numb. People experience the feeling of a muscle biopsy differently because of different pain thresholds and how the numbing medicine works in any individual. You may feel very little or only a charley horse sensation, or you may feel more distinct pain. After the study, you have a chance of experiencing soreness at the site of muscle sample collection for 24 to 48 hours. However, over-the-counter medications such as Tylenol and cold packs are enough to control such a discomfort. There is also a very rare possibility of numbness around the site of muscle sample collection. This is typically temporary and should resolve within a few months. The muscle sample collection may leave a scar approximately long like this dash “\_”.

Lidocaine use with the 90-day muscle biopsy: Minor pain at the injection site and

Page 12 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

brief stinging may occur. A possible side-effect is an anaphylactic reaction (a severe allergic reaction to the Lidocaine) that could result in symptoms such as shortness of breath, swelling of the throat, inflammation of the skin, skin rash, low blood pressure and death (rare).

**Breach of confidentiality:** It is possible that someone could find out that you were in this study and could find out information about you. Every effort will be made to prevent this from happening. To protect your confidentiality, we will remove your name and other personal identifiers from the samples and from the medical record information we obtain. This information will be identified by a code.

**Risks associated with gene studies:** The risks associated with gene studies include the potential for a breach of confidentiality which could affect future insurability, employability, or reproduction plans, or have a negative impact on family relationships and/or result in paternity suits or stigmatization.

In addition, there is a Federal law, called the Genetic Information Nondiscrimination Act (GINA), that generally makes it illegal for health insurance companies and group health plans to use genetic information in making decisions regarding your eligibility or premiums. GINA also makes it illegal for employers with 15 or more employees to use your genetic information when making decisions regarding hiring, promoting, firing, or setting the terms of employment. This new Federal law does not protect you against genetic discrimination by companies that sell life, disability, or long-term care insurance.

To facilitate communication during the study, this study will use e-mails to update the study team of your progress in the study. This may include the use of your name and other personal identifiers to ensure accurate information. Although every reasonable effort has been taken, confidentiality during Internet communication activities cannot be guaranteed and it is possible that additional information beyond that collected for research purposes may be captured and used by others not associated with this study.

As with any experimental procedure, there may be adverse events or side effects that are currently unknown and certain of these unknown risks could be permanent, severe or life-threatening.

## ANTICIPATED BENEFITS TO SUBJECTS

For those subjects assigned to the placebo group (no metformin will be taken), no direct benefit from study participation is expected. For those subjects who will be taking metformin, it is not known if there will be any direct benefit to you from being in the research study.

## ALTERATIVE TREATMENTS

There are no alternative procedures which may be of benefit to you if you choose not to participate in this research study.

Page 13 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

## NEW INFORMATION

You will be promptly notified if any new information we learn during this research study may cause you to change your mind about continuing to participate in the study.

## COSTS AND PAYMENTS

If you agree to take part in this research study, you and/or your insurance will not have to pay for the study drug or any tests that are being done only for the research study. However, you are still responsible for paying for elective surgery and hospital admission as well as other care you would normally receive. This includes treatments and tests you would need even if you were not in this study. These costs will be billed to you and/or your insurance.

If you complete the entire study, you may be paid up to \$200 in return for your time and effort associated with research study involvement. These funds will be provided to you as \$50 payments 4 times throughout the study:

\$50 following the clinic visit before surgery

\$50 following the hospital stay

\$50 following the phone call at roughly 30 days after surgery

\$50 following the phone call/visit at roughly 90 days after surgery

In addition, if you participate in the Microbiome Sub-study, you will be paid \$20 for each of the stool samples and rectal swab collected for this study for a total of \$80 over the course of the study.

You will receive this compensation via a reloadable debit card. The debit card is not loaded with funds until you coordinate with the study team to load the card with funds. Since you are being compensated for your participation in this study, your name, address, and social security number will be released to the Accounting Office. If you are not comfortable with providing your social security number for use by the Accounting Office, taxes will automatically be removed from the payment.

## USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION

We are also requesting your authorization or permission to review your medical records. This research study may involve the recording of past, current and/or future identifiable medical information from your hospital and/or other (e.g. physician office) records to determine whether you meet the conditions for participation in this study. The information that may be recorded will include information concerning your medical history, results of lab tests, diagnostic procedures, the reason for your elective surgical procedure, and the type of medical insurance you have. In addition, medical record information related to your hospital stay for your elective surgery and any follow-up visits may be recorded to assess the effects of the study drug. As part of this research

Page 14 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

study, some information that we obtain from you may be placed into your medical records held at UPMC, including the results of any testing performed specifically for this research study. This authorization to provide identifiable information available to members of the study team is valid for an indefinite period of time.

In addition to the Principal Investigator listed on the first page of this consent form and the other investigators involved in this study and the study team, the following individuals will or may have access to identifiable information (which may include your identifiable medical information) related to your participation in this research study:

- Authorized representatives of the University of Pittsburgh Research Conduct and Compliance Office for the purpose of monitoring the appropriate conduct of this research study.
- Authorized representatives of UPMC or other affiliated health care providers for the purpose of (1) fulfilling orders made by the investigators for hospital and health care services (e.g., diagnostic procedures) associated with research study participation; (2) addressing correct payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital operations (e.g., quality assurance).

We will protect your privacy and the confidentiality of your records, as described in this document, but cannot guarantee the confidentiality of your research records, including information obtained from your medical records, once your personal information is disclosed to others outside UPMC or the University.

In addition, coded data about your participation in this study will be shared with Berry Consultants, LLC, a collaborator, and an external Data Safety and Monitoring Board (DSMB). The DSMB will review this coded data for the purpose of overseeing study progress and evaluating the potential risks to subjects associated with study participation.

We may send your de-identified muscle biopsy samples for analysis to investigators at the University of Pittsburgh and/or to other collaborators such as the University of Utah for analysis. The linkage document containing your name and your study ID will not be shared with these research teams. Descriptors such as your age and gender may be shared but no identifiable information.

We may share your responses from the EQ-5D questionnaires with your health care providers.

A description of this clinical trial will be available on <http://www.clinicaltrials.gov>, as required by US Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.



## MEDICAL CARE FOR RESEARCH RELATED INJURY

If you believe that the research procedures have resulted in an injury to you, immediately contact the Principal Investigator who is listed on the first page of this form. Emergency medical treatment for injuries solely and directly related to your participation in this research study will be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the costs of this emergency treatment, but none of those costs will be charged directly to you. If your research-related injury requires medical care beyond this emergency treatment, you will be responsible for the costs of this follow-up care. At this time, there is no plan for any additional financial compensation. You do not, however, waive any legal rights by signing this form.

## VOLUNTARY PARTICIPATION

Your participation in this research study is entirely voluntary. You may want to discuss this study with your family and friends and your personal physician before agreeing to participate. If there are any words you do not understand, feel free to ask us. The investigators will be available to answer your current and future questions.

Whether or not you provide your consent for participation in this research study will have no effect on your current or future relationship with the University of Pittsburgh. Whether or not you provide your consent for participation in this research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health care provider or your current or future relationship with a health care insurance provider.

As both your doctor and a research investigator, s/he is interested both in your medical care and the conduct of this research study. Before agreeing to participate in this research study, or at any time during your study participation, you may discuss your care with another doctor who is not associated with this research study. You are not under any obligation to participate in any research study offered by your doctor.

To formally withdraw your consent for participation in this research study, you should provide a written and dated letter of this decision to the principal investigator of this research study at the address listed on the first page of this form.

## RIGHT TO WITHDRAW

It is possible that you may be removed from the research study by the researchers if, for example,





- You do not or cannot take the study drug properly.
- The researcher feels it is in your best interest not to continue in the study.
- The funding for the study is not continued.
- There may be other reasons to remove you from the study not identified at present.

In the event of study withdrawal, you will be asked to return the study drug pill bottle to the study team using a pre-paid mailing envelope.

Upon your withdrawal from this study, you should participate in additional monitoring follow-up procedures that are being conducted to measure the safety of the study drug.

All information obtained from you up until the date of your withdrawal from the study will be maintained in a coded fashion. No further data will be collected following your withdrawal from the study. Your blood and stool samples which have been placed into storage may continue to be used for analysis, but no further samples will be collected from you for this study.



#### **VOLUNTARY CONSENT TO PARTICIPATE:**

Page 17 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

The above information has been explained to me and all of my current questions have been answered. I understand that I am encouraged to ask questions, voice concerns or complaints about any aspect of this research study during the course of this study, and that such future questions, concerns or complaints will be answered by a qualified individual or by the investigator listed on the first page of this consent document at the telephone number given.

I understand that I may always request that my questions, concerns or complaints be addressed by a listed investigator. I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions; obtain information; offer input; or discuss situations that occurred during my participation. By signing this form, I agree to participate in this research study and provide my authorization to share my medical records with the study team. A copy of this consent form will be given to me.

\_\_\_\_\_  
Printed Name of Participant

\_\_\_\_\_  
Signature of Participant

\_\_\_\_\_  
Date

\_\_\_\_\_  
Time

### INVESTIGATOR CERTIFICATION:

*I certify that I have explained the nature and purpose of this research study to the above-named individual(s), and I have discussed the potential benefits and possible risks of study participation. Any questions the individual(s) have about this study have been answered, and we will always be available to address future questions, concerns or complaints as they arise. I further certify that no research component of this protocol was begun until after this consent form was signed.*

\_\_\_\_\_  
Printed Name of Person Obtaining Consent

\_\_\_\_\_  
Role in Research Study

\_\_\_\_\_  
Signature of Person Obtaining Consent

\_\_\_\_\_  
Date

\_\_\_\_\_  
Time

### CONSENT FOR OPTIONAL GROUPS AND SUB-STUDIES

Page 18 of 19



University Of Pittsburgh  
Institutional Review Board

Approval Date: 1/17/2020  
Renewal Date: 9/16/2020

IRB #: PRO18060038

You are being asked to confirm your interest in participating in the following optional groups and sub-studies which have been explained in the preceding pages:

Initials of person obtaining informed consent indicating Group/Sub-study is available*	Title of Group/Sub-Study	Initials of this subject indicating their interest in Group/Sub-study*
	Motor Assessment Group (involves in person visit around 90 days after surgery instead of phone call and involves grip strength and two-minute walk tests)	
	Microbiome Sub-study (involves stool sample collections and rectal swab)	
	Muscle Biopsy Sub-study (involves up to 2 muscle biopsies)	

\* Initials are required in both the first and third column for Sub-study participation.

